Phase II Trial of Irinotecan in Children With Relapsed or Refractory Rhabdomyosarcoma: A Joint Study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group
- 1 February 2007
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (4), 356-361
- https://doi.org/10.1200/jco.2006.06.1960
Abstract
Purpose: This phase II study was designed to evaluate the efficacy of irinotecan administered intravenously once every 3 weeks in pediatric patients with recurrent or refractory rhabdomyosarcoma. Patients and Methods: A total of 35 patients younger than age 20 years, with refractory or relapsed rhabdomyosarcoma for which standard treatments have failed, received irinotecan at 600 mg/m2 administered as a 60-minute infusion every 3 weeks. Concomitant treatments included atropine for cholinergic symptoms, loperamide for diarrhea at the first liquid stool, and preventive antiemetic treatment. Tumor response was assessed every two cycles until progression according to WHO criteria. Results: The best overall response rate to irinotecan was 11.4% (95% CI, 3.2 to 26.7%; 2.9% complete responses, 8.5% partial responses) from all patients recruited. The median times to progression and survival were 1.4 and 5.8 months, respectively. A total of 112 cycles were administered, with a median number of two cycles per patient (range, 1 to 16). The most common grade 3/4 toxicities were neutropenia (46%), abdominal pain or cramping (17%), cholinergic syndrome (14%), nausea/vomiting (11%), anemia (11%), thrombocytopenia (9%), and diarrhea (6%). Conclusion: In heavily pretreated children with a high tumor burden who have been treated with multiagent chemotherapy, irinotecan administered intravenously as a single agent, at 600 mg/m2 every 3 weeks, showed an interesting objective response rate and a good tolerance profile in rhabdomyosarcoma.Keywords
This publication has 19 references indexed in Scilit:
- Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcomaCancer, 2005
- Treatment of Nonmetastatic Rhabdomyosarcoma in Childhood and Adolescence: Third Study of the International Society of Paediatric Oncology—SIOP Malignant Mesenchymal Tumor 89Journal of Clinical Oncology, 2005
- A phase I study of irinotecan administered on a weekly schedule in pediatric patientsPediatric Blood & Cancer, 2005
- European Intergroup Studies (MMT4-89 and MMT4-91) on Childhood Metastatic Rhabdomyosarcoma: Final Results and Analysis of Prognostic FactorsJournal of Clinical Oncology, 2004
- A Phase I Study of Irinotecan As a 3-Week Schedule in Children With Refractory or Recurrent Solid TumorsJournal of Clinical Oncology, 2003
- Prognostic Factors and Clinical Outcomes in Children and Adolescents With Metastatic Rhabdomyosarcoma—A Report From the Intergroup Rhabdomyosarcoma Study IVJournal of Clinical Oncology, 2003
- Phase I Study of Irinotecan in Pediatric Patients With Malignant Solid TumorsJournal of Pediatric Hematology/Oncology, 2002
- The Development of Camptothecin Analogs in Childhood CancersThe Oncologist, 2001
- Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenograftsCancer Chemotherapy and Pharmacology, 1996
- A Confidence Interval for the Median Survival TimePublished by JSTOR ,1982